Myostatin, a member of the transforming growth factor-β superfamily, has been implicated in
the potent negative regulation of myogenesis in murine models. However, little is known …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …

Myostatin is a negative regulator of skeletal muscle growth. Myostatin mutations and
pharmacological strategies increase muscle mass in vivo, suggesting that myostatin …

In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

Abstract Background Myostatin (Mstn) and growth/differentiation factor 11 (Gdf11) are highly
related transforming growth factor β (TGFβ) family members that play important roles in …

Myostatin is a secreted growth and differentiation factor that belongs to the TGF‐β
superfamily. Myostatin is predominantly synthesized and expressed in skeletal muscle and …

Skeletal muscle is the largest organ in the human body, and plays an important role in body
movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as …

Human aging is accompanied by a progressive loss of muscle mass (sarcopenia). We tested
the hypothesis that older males (OMs, 70±4 yr, n= 9) would have a blunted myogenic …

In this issue of the Journal, Schuelke et al.(pages 2682–2688) describe a child with
substantial muscle hypertrophy and a splice-site mutation in the gene encoding myostatin …

Myostatin, a transforming growth factor–β family member, is a negative regulator of skeletal
muscle growth. To explore the therapeutic potential of targeting myostatin in settings of …